-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
The addition of cytotoxic chemotherapy to immune checkpoint inhibitors (ICI) enhances antitumor effects
The study recruited patients with histologically definitive diagnosis of stage IIIB/IIIC/IV or postoperative recurrence who had previously received first- or second-line chemotherapy and were randomly divided into two groups
A total of 128 patients (64 in each group) were enrolled in the overall analysis population
Hematoxicity and gastrointestinal adverse reactions when navumab is combined with docetaxel are more common
Overall, although toxicity is slightly elevated, the addition of docetaxel to navumab significantly prolongs the overall survival and progression-free survival of patients with ICI who have previously been treated with ICI
Original source:
Yuri Taniguchi, Tsuneo Shimokawa, Yuichi Takiguchi, et al.